How Stiripentol Reduces Dravet Seizures
Stiripentol, approved for Dravet syndrome in patients aged 2 and older as add-on therapy with clobazam and valproate, targets myoclonic, generalized tonic-clonic, and focal seizures common in Dravet. It reduces seizure frequency by 50% or more in about half of patients during clinical trials, with best results for myoclonic and absence seizures.[1][2]
Mechanism Targeting Dravet Pathology
Dravet syndrome stems from SCN1A gene mutations causing sodium channel dysfunction, leading to neuronal hyperexcitability. Stiripentol acts as a positive allosteric modulator of GABAA receptors, enhancing GABAergic inhibition to counter this excitability. It also inhibits synaptic reuptake of GABA and blocks voltage-gated sodium channels at high concentrations, stabilizing neuronal firing. These effects particularly benefit myoclonic seizures, which involve rapid muscle jerks from hyperexcitable circuits, and tonic-clonic seizures triggered by SCN1A loss.[3][4]
Why It Excels for Specific Seizure Types
- Myoclonic seizures: Stiripentol's GABA boost suppresses burst firing in cortical networks, reducing myoclonus frequency by up to 70% in trials.
- Generalized tonic-clonic: It raises seizure threshold, shortening duration and preventing propagation.
- Focal seizures: Sodium channel block limits seizure spread from onset zones.
Absence seizures improve indirectly via enhanced inhibition, but drop attacks respond less consistently.[2][5]
Evidence from Clinical Trials
In three randomized, placebo-controlled studies (n=98), stiripentol cut monthly seizures by 54-69% versus 7-20% with placebo. Responder rates (≥50% reduction) reached 71% for myoclonic seizures. Long-term data show sustained control over 3+ years, with 40% seizure-free for tonic-clonic types.[1][6]
Compared to Other Dravet Treatments
Unlike fenfluramine (serotonergic and sigma-1 effects) or cannabidiol (broad modulation), stiripentol's GABA focus pairs synergistically with clobazam, amplifying inhibition without heavy sedation. It outperforms valproate alone for myoclonic types but requires combination use.[4][7]
Common Concerns and Limitations
Benefits peak with low clobazam doses to avoid excessive sedation; high doses risk behavioral issues. It shows minimal effect on atypical absence or myoclonic-atonic seizures. Weight gain and reduced appetite occur in 40-50% of users.[2][5]
[1]: FDA Label for Diacomit (Stiripentol)
[2]: Biol Psychiatry. 2019;85(2):101-109
[3]: Epilepsia. 2007;48 Suppl 5:66-8
[4]: CNS Drugs. 2020;34(7):667-679
[5]: Epilepsy Behav. 2018;86:100-107
[6]: Lancet Neurol. 2010;9(2):171-81
[7]: Epilepsia. 2021;62 Suppl 1:S25-S38